Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Neoadjuvant immunotherapy combo produces high response rate in melanoma

Key clinical point: Combination neoadjuvant nivolumab and CMP-001 is efficacious in patients with high-risk resectable melanoma.

Major finding: Fully 60% of patients achieved a major pathologic response, and those who did had a 1-year relapse-free survival rate of 89%.

Study details: A single-arm, phase 2 trial of neoadjuvant nivolumab and CMP-001 in 31 patients with stage IIIB/C/D melanoma having clinically apparent lymph node disease (Neo-C-Nivo trial).

Disclosures: The trial was funded by Checkmate Pharmaceuticals. Dr. Davar disclosed relationships with Checkmate Pharmaceuticals, Array Biopharma, Merck, Shionogi, Vedanta, Bristol-Myers Squibb, CellSight Technologies, GlaxoSmithKline/Tesaro, and Medpacto.


Davar D et al. SITC 2020, Abstract 303.